NASDAQ:ICLR - Icon Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$137.03 +0.70 (+0.51 %)
(As of 06/24/2018 05:08 AM ET)
Previous Close$137.03
Today's Range$134.08 - $138.17
52-Week Range$95.06 - $138.17
Volume193,420 shs
Average Volume186,706 shs
Market Capitalization$7.37 billion
P/E Ratio25.42
Dividend YieldN/A
Icon logoICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research


Debt-to-Equity Ratio0.29
Current Ratio1.85
Quick Ratio1.85


Trailing P/E Ratio25.42
Forward P/E Ratio22.65
P/E Growth2.14

Sales & Book Value

Annual Sales$1.76 billion
Price / Sales4.21
Cash Flow$6.6326 per share
Price / Cash20.66
Book Value$22.02 per share
Price / Book6.22


EPS (Most Recent Fiscal Year)$5.39
Net Income$281.48 million
Net Margins14.80%
Return on Equity26.56%
Return on Assets14.53%


Outstanding Shares54,080,000

The Truth About Cryptocurrencies

Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) announced its earnings results on Thursday, May, 3rd. The medical research company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.01. The medical research company earned $620.13 million during the quarter, compared to the consensus estimate of $562.61 million. Icon had a net margin of 14.80% and a return on equity of 26.56%. The firm's revenue for the quarter was up 43.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.29 EPS. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $5.91-6.11 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.99. The company issued revenue guidance of $2.52-2.64 billion, compared to the consensus revenue estimate of $2.25 billion.

What price target have analysts set for ICLR?

10 brokerages have issued 12 month target prices for Icon's shares. Their predictions range from $114.00 to $152.00. On average, they anticipate Icon's share price to reach $130.70 in the next twelve months. View Analyst Ratings for Icon.

Who are some of Icon's key competitors?

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Mr. Ciaran Murray, Former Exec. Chairman (Age 55)
  • Dr. Steven A. Cutler, CEO & Director (Age 58)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 39)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer

Has Icon been receiving favorable news coverage?

News stories about ICLR stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Icon earned a news sentiment score of 0.09 on Accern's scale. They also assigned media stories about the medical research company an impact score of 45.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Icon's major shareholders?

Icon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include WCM Investment Management CA (8.25%), Earnest Partners LLC (4.01%), Wasatch Advisors Inc. (3.07%), Boston Partners (3.01%), Wells Fargo & Company MN (1.93%) and Principal Financial Group Inc. (1.75%). View Institutional Ownership Trends for Icon.

Which major investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Earnest Partners LLC, Envestnet Asset Management Inc., Wasatch Advisors Inc., Victory Capital Management Inc., Fiera Capital Corp, Wells Fargo & Company MN and Loomis Sayles & Co. L P. View Insider Buying and Selling for Icon.

Which major investors are buying Icon stock?

ICLR stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, WCM Investment Management CA, Principal Financial Group Inc., Principal Financial Group Inc., Lord Abbett & CO. LLC, Massachusetts Financial Services Co. MA, American Century Companies Inc. and Baird Financial Group Inc.. View Insider Buying and Selling for Icon.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $137.03.

How big of a company is Icon?

Icon has a market capitalization of $7.37 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. Icon employs 13,250 workers across the globe.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.

MarketBeat Community Rating for Icon (ICLR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  645
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.